Source Neurology Advisor:
VANCOUVER, British Columbia — For the treatment of secondary-progressive multiple sclerosis (SPMS), NDC-1308−a small molecule that activates intracellular pathways for oligodendrocyte progenitor cell (OPC) differentiation−showed favourable pharmacokinetic properties and was safe in a mice study. Read on.